Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy-A Single-Center Prospective Cohort Study
异基因造血干细胞移植或基于 CD19 的 CART 治疗后患者中 BNT162b2 mRNA COVID-19 疫苗的安全性和免疫原性——一项单中心前瞻性队列研究
期刊:Transplantation and Cellular Therapy
影响因子:3.2
doi:10.1016/j.jtct.2021.06.024
Ron Ram, David Hagin, Nino Kikozashvilli, Tal Freund, Odelia Amit, Yael Bar-On, Ofrat Beyar-Katz, Gabi Shefer, Miguel Morales Moshiashvili, Chen Karni, Ronit Gold, Sigi Kay, Chen Glait-Santar, Rinat Eshel, Chava Perry, Irit Avivi, Arie Apel, Noam Benyamini, David Shasha, Ronen Ben-Ami
